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Abstract (145 words): Leukemias are highly immunogenic but have a low mutational load, 
providing few mutated peptide targets. Thus, the identification of alternative neoantigens is a 
pressing need. Here, we identify 36 MHC class I–associated peptide antigens with O-linked 
β-N-acetylglucosamine (O-GlcNAc) modifications as candidate neoantigens, using three 
experimental approaches. Thirteen of these peptides were also detected with disaccharide 
units on the same residues and two contain either mono- and/or di-methylated arginine 
residues. A subset were linked with key cancer pathways, and these peptides were shared 
across all of the leukemia patient samples tested (5/5). Seven of the O-GlcNAc peptides 
were synthesized and five (71%) were shown to be associated with multifunctional memory 
T-cell responses in healthy donors. An O-GlcNAc-specific T-cell line specifically killed 
autologous cells pulsed with the modified peptide, but not the equivalent unmodified peptide. 
Therefore, these post-translationally modified neoantigens provide logical targets for cancer 
immunotherapy. 
Introduction 
The role of antitumor immunity has been an intense focus of research for many decades (1-
4).  Although it is clear from strong correlative clinical data, combined with definitive 
experimental evidence from mouse cancer models, that T cells mediate this protection, the 
nature of the antigens targeted remains poorly characterized.  Over the past decade the role 
of altered-self antigens, termed neoantigens, has become clear (5-9).  Tumor-specific 
neoantigens act as targets for spontaneously arising adaptive immunity to cancer and 
thereby determine the ultimate fate of developing tumors (7). Nonsynonymous mutations in 
coding regions of expressed proteins are termed mutational neoantigens and, perhaps 
critically, are not subject to central tolerance.  In patients with cancers that have high 
mutational loads, such as non-small cell lung cancer and melanoma, CD8+ T cells can be 
identified within the tumor that are specific for MHC class I–restricted neoantigens in 
response to immunotherapy (10, 11).  However, tumor-resident immunity against mutational 
neoantigens occurs at very low frequencies and it would be surprising if this magnitude of 
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immunity could be responsible for the dramatic reductions in tumor volume seen (7, 12).  
Additionally, some of the tumors with the best clinical responses to immunotherapy have 
some of the lowest mutational loads, for example, renal cell carcinomas and leukemias (12-
14).  Hematological malignancies, in particular, are known to be among the most 
immunogenic cancers (15).  Therefore, it is likely that the antigens in these malignancies 
derive from other classes of antigens.   
An alternative source of neoantigens may be the posttranslational modifications (PTMs) that 
occur in malignant and not healthy cells, particularly as dysregulated signaling is a hallmark 
of cancer (16). Indeed, a number of phosphorylated peptides have been identified as potent 
cancer antigens(17). Immunity to these antigens was seen in healthy donors, but lost in a 
subset of leukemia patients with poor clinical outcome and restored after stem cell 
transplant, suggesting a role for these antigens in the graft-versus-leukemia response. 
Dysregulation of cell signaling pathways in cancer is also caused by another PTM, β O-
linked N-acetylglucosamine (O-GlcNAc), which is involved in cross-talk with phosphorylation 
(18-20). As such, aberrant O-GlcNAcylation can correlate with augmented cancer cell 
proliferation, survival, invasion, and metastasis (21). Synthetic O-GlcNAc–modified peptides 
can bind MHC class I complexes, and elicit glycopeptide-specific T-cell responses in mice, 
with X-ray structures confirming that the O-GlcNAc group was solvent exposed and 
accessible to the T-cell receptor (22-25). However, up until recently, limitations in proteomic 
technology made it impossible to characterize O-GlcNAcylated peptides from biological 
samples.  
Here, we report three experimental approaches that allowed the detection and sequencing of 
O-GlcNAcylated peptides from a complex mixture of peptides presented by HLA-B*07:02 
molecules on various primary leukemia samples. These methods allowed for the 
identification of 36 unique glycopeptides in several different states of glycosylation and, 
surprisingly, methylation. We go on to show that healthy donors have heterologous immunity 
to a number of these complex neoantigens and that T cells from these donors can 
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specifically target and kill cells displaying only the modified peptide. Ultimately, we believe 
that these glycopeptide antigens will prove pivotal in the design of novel cancer 
immunotherapeutics. 
Materials and Methods 
Leukemia samples and cell lines. Leukemia samples were the same as those used 
previously (Supplementary Table S1)(17). All cell lines were grown at 37ºC with 5% CO2 in 
medium consisting of RPMI 1640 supplemented with 10% fetal bovine serum (all from 
Sigma-Aldrich, St. Louis, MO). The JY cell line (ECACC – 94022533) was grown continually 
between 2006 and 2008 with its authenticity verified by HLA-typing and also in-house 
peptide profile. 
Isolation of HLA-associated peptides. Class I MHC molecules were immunoaffinity-
purified from cell lines or tumors and their associated peptides were extracted as described 
previously(17). Cells (108-109) were lysed in 10 mL of CHAPS buffer (Sigma-Aldrich, St. 
Louis, MO) and the lysate was centrifuged at 100,000 x g for 1 hour at 4°C. Supernatants 
were passed over protein A-sepharose preloaded with HLA-B7 specific antibody (ME1). 
Peptides were eluted from the purified MHC class I molecules with 10% acetic acid and 
separated by ultrafiltration (Ultrafree-MC, Millipore, Billerica, MA). 
Enrichment of HLA-associated peptides. POROS20 AL beads (Applied Biosystems, 
Carlsbad, CA) were derivatized with amino-phenyl boronic acid (APBA; Thermo Fisher 
Scientific, Waltham, MA).  Briefly, POROS20 beads (7 mg) were dispersed into 200 µL of 
PBS (pH 6-7) containing 40 µmol of APBA. Following the addition of NaCNBH3 (1.3 µmol in 
1 µL of PBS), the reaction was allowed to proceed with agitation for 2 hr at RT and then 
quenched by washing the beads with water on a spin column (pore size < 20 µm). Water 
was removed under vacuum and the dried beads were stored at 4°C.  
Class I MHC peptides from 2 x108–5 x108 cells in 0.1% acetic acid were desalted by loading 
the solution onto a fused-silica column (360 µm o.d. x 150 µm i.d.) packed in-house with 5 
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cm of irregular C18 (5–20 μm diameter) particles at a flow rate of 0.5 µl/min. After washing 
the column with 25 µL of 0.1% acetic acid, peptides were eluted into Eppendorf tubes with a 
40 min gradient (0-80%) solvent B (A: 0.1M acetic acid, B: 70% acetonitrile, 0.1M acetic 
acid).  Fractions were screened by MS and those that contained peptides, but not CHAPS 
detergent, were combined, taken to dryness and stored at -35°C. 
APBA-beads were washed 3x with 100 µl of anhydrous DMF and then allowed to react with 
desalted peptides in 20 µl of anhydrous DMF for 1 hour with agitation.  Solvent was removed 
by centrifugation and the beads were washed 2x with 100 µL of anhydrous acetonitrile. 
Bound peptides were released by agitating the beads in 20 µL of 0.1 M acetic acid for 30 
min.  Supernatant was collected, taken to dryness, and reconstituted in 10 μL of 0.1M acetic 
acid for loading onto an in-house packed C18 column for MS analysis. 
RP-HPLC-MS. In-house, packed C18 columns were prepared as previously described(26). 
Peptides were eluted by a 2 hour 0-60% B gradient (A: 0.1M acetic acid, B: 70% ACN, 0.1M 
acetic acid). Without enrichment, samples were loaded directly onto the C18 column. The 
RP-HPLC elution was electrospray-ionized into an Orbitrap Velos, or Orbitrap Fusion Tribrid 
mass spectrometer (Thermo Scientific, San Jose, CA), the former equipped with an in-house 
front-end ETD ion source. On the Orbitrap Velos, the instrument method was a top-10 CAD 
with ETD only when loss of dehydro-GlcNAc neutral loss of [203]+2 or [203]+3 was detected. 
On the Fusion, instrument method was a top speed HCD triggered ETD when three of six O-
GlcNAc fingerprint ions (m/z 204, 186, 168, 144, 138, and 126) were detected at >5% 
relative abundance. Peptide sequences were determined by manual interpretation of HCD, 
CAD, and ETD mass spectra. 
Synthetic Peptides. O-GlcNAc- and O-GalNAc-peptides were synthesized using Fmoc 
chemistry and purified by HPLC to >90% purity by Pierce Biotechnology, Rockford, Il.  
Sequences and purity for all synthetic peptides were confirmed by on-line HPLC MS/MS and 
manual interpretation of the resulting spectra. Immunodominant HLA-B*0702 restricted 
antigens from human cytomegalovirus (pp65417–426, TPRVTGGGAM); Epstein-Barr virus 
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(EBNA-3A247-255, RPPIFIRRL) and Influenza A virus (PB1329-337, QPEWFRNVL) were 
synthesized at >90% purity by Genscript, Piscataway, NJ. 
Selective transfer of N-azidoacetylgalactosamine (GalNAz) to O-GlcNAcylated 
peptides. A solution of the modified β1-4-galactosyltransferase, GalT1 (Invitrogen, 
Carlsbad, CA), was dried to 5 μL in a vacuum concentrator at 40°C. Excess synthetic 
glycopeptides or tumor peptides (3e8 cell equivalents) were taken to dryness, redissolved in 
a mixture containing 1 μL MnCl2, 5 μL uridinediphosphate N-azidoacetylgalactosamine, 
UDP-GalNAz (Invitrogen, Carlsbad, CA), and 5 μL enzyme and allowed to react for 5 hours 
at RT. After the reaction was quenched by addition of 0.2 μL glacial acetic acid, the solution 
volume was increased to 15 μL with 0.1% acetic acid, and then loaded directly onto an 
HPLC column for analysis by LC-MS/MS.  
Intracellular cytokine staining. PBMCs were isolated from healthy donors and 
resuspended (106 cells/ml) in AIM-V medium (Invitrogen, Carlsbad, CA).  Synthetic peptide 
antigens were added to the wells (10 μg/mL) and cells were expanded for 6 days. The 
positive control was stimulated with PHA (1 μg/ml).  On day 6, cells were washed and re-
stimulated with peptide antigen overnight or, for the positive control, with PMA/Ionomycin (4 
ng/ml and 500 ng/ml respectively), in the presence of anti-CD107a–FITC. Cells were 
harvested, washed with PBS, and stained with fixable viability dye (APC-Cy7) and surface 
antibodies: anti-CD3and anti-CD8 . Cells were fixed using 2% formaldehyde, permeablized 
using 0.5% saponin, and stained with anti-IFNγ–PE, anti-IL2–Pacific blue, and anti-TNFα–
PE-Cy5.5 for 30 minutes at RT. Cells were washed, lightly fixed, and analyzed on the 
LSRFortessa X20 flow cytometer (BD Bioscience, Oxford, UK). A list of antibodies used in 
the study is shown in Table S2 
Establishment of a peptide-specific T-cell line. PBMCs (107) were stimulated with 
synthetic peptide and cultured for a week. They were subsequently restimulated overnight, in 
the presence of anti-CD107a–FITC and washed and labelled with anti-CD137–PE (Miltenyi 
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Biotech, Bergisch Gladbach, Germany) and counterstained with anti-CD8–APC (Biolegend). 
Cells were sorted using a FACS Aria cell sorter (BD Bioscience), collected and expanded 
using the rapid expansion protocol previously described(27). The T-cell line was 
subsequently reassessed, using a similar protocol.  
Europium Release Killing Assay. The Delfia EuTDA cytotoxicity assay (Perkin Elmer, 
Coventry, UK) was used according to the manufacturer’s instructions.  Briefly, autologous 
transformed B-cell lines were used as target cells. These were washed and resuspended at 
106 cells/ml in RPMI 10% FCS and, the relevant peptide antigen was added at 10 µg/ml and 
the mixture was incubated at 37°C, 5% CO2 in a humidified environment for 40 min.  
Subsequently, 2.5 μL/ml of the BATDA fluorescence enhancing ligand was added and the 
cells were incubated for a further 20 min. Cells were then washed 5x in excess medium.  
Target cells (104) were added to each well of a V-bottomed 96-well plate. T cells at varying 
effector to target (E:T) ratios were added to the test wells. All well volumes were made up to 
200 μL. The plate was incubated for 2 hr at 37°C, 20 µl of each supernatant was transferred 
to a flat bottomed, white, 96 well plate and 200 μL of Europium solution was added, 
incubated for 15 min, with shaking, at room temperature.  Fluorescence was measured with 
a time-resolved fluorometer (Tecan Infinite 200 PRO, Tecan, Switzerland). 
Results 
Experimental approaches that allow identification of O-GlcNAcylated peptide antigens 
Three different experimental approaches were used to identify peptides with O-GlcNAc 
modifications from leukemia patient samples. The first approach used higher energy 
collision–induced dissociation (HCD) mass spectrometry (MS) to visualize the loss of a 
dehydro-N-acetyl-glucosamine moiety (203Th) from fragment ions. The HCD mass spectrum 
of the first O-GlcNAcylated class I MHC peptide, XPVsSHNSX (where X=I or L), detected 
during analysis of HLA B*07:02 peptides presented on ALL, is shown in Fig.  1A. The amino 
acid sequence, XPVsSHNSX, is uniquely present as IPVSSHNSL in a single human protein, 
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myocyte-specific enhancer factor 2C. This approach is limited by the ability of 
nonglycosylated peptides to suppress electrospray ionization of co-eluting O-GlcNAcylated 
peptides(28).  
The second approach overcomes this limitation and allows detection and characterization of 
O-GlcNAcylated peptides from attomole quantities, using an enrichment procedure to 
selectively pull down the glycosylated peptides from the pool of unmodified peptides. The 
enrichment allowed selective esterification of glycosylated peptides, linking them to 
aminophenylboronic acid–derivatized POROS AL 20 beads. This O-GlcNAc enrichment 
procedure allowed us to achieve quantitative yields from femtomoles of starting material, and 
may be critical for efficient identification of these antigens from patient samples. This 
methodology was used in combination with an instrument method that selectively recorded 
electron transfer dissociation (ETD) when the collision-activated dissociation (CAD) 
spectrum contained a doubly charged ion corresponding to the loss of dehydro-N-acetyl-
glucosamine (203Th)(29).  
The third experimental approach extended the sensitivity of the method and allowed the user 
to obtain spectral information from extremely low-level peptide species. This was achieved 
using an instrument method that triggered an ETD spectrum whenever three of six O-
GlcNAc fingerprint ions (m/z 204, 186, 168, 144, 138, and 126) were detected at >5% 
relative abundance in a particular HCD spectrum when the Orbitrap Fusion Tribrid was set to 
record HCD spectra at top speed. All of thefingerprint ions in Fig.  1B were the result of the 
O-GlcNAc oxonium ion at m/z 204 undergoing further fragmentation as a result of multiple 
collisions with the background nitrogen gas in the collision chamber. The use of multiple 
fingerprint fragments created a reliable trigger that minimized false positives. 
36 O-GlcNAcylated peptides identified on HLA B*07:02 leukemia samples 
In total, using the three experimental approaches outlined, 36 O-GlcNAcylated peptides 
were identified from leukemia samples (Table 1). 92% (33/36) of the O-GlcNAcs identified 
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were only found on the leukemia samples tested and not the healthy tissue samples, making 
them potential leukemia neoantigens (Table 1, Fig. 1C, Supplementary Fig. S1). Just 
under a quarter (7/32) of the proteins that the O-GlcNAcylated peptides derived from were 
associated with key cancer pathways (as defined by the NCI pathway interaction database, 
which is now accessible via the NDEx database at http://www.ndexbio.org/#/). These pathways 
included many classical cancer signaling pathways, involving genes such as p38, p53, c-
Myc, Notch, Wnt, Rb, ErbB1, and MAPK. Of note, IPVsSHNSL, which derives from Mef2c, a 
transcription factor implicated in leukemogenesis(30), was identified on nearly all of the 
leukemia samples tested (1/1 ALL, 3/3 CLL, 1/1 AML) and although it could be detected on 
healthy B cells, it was present in far lower amounts (Fig.  1D). An incidental, but significant, 
finding was that one of the O-GlcNAcylated peptides detected, RPPItQSSL, contained 
another PTM – a methylated Arg residue at P1 and was also found with an asymmetrically 
dimethylated Arg residue (Supplementary Fig. S2).  
Distinguishing O-GlcNAc from O-GalNAc 
Because O-GlcNAc and O-GalNAc are isobaric, but have different biological properties, it 
was important to confirm that the peptides we identified indeed contained O-GlcNAc 
modifications, and not O-GalNAc. Furthermore, some MHC class I peptides we observed 
contained disaccharide units (see footnotes for Table 1), so they might have been derived 
from degradation of O- and N-linked glycans synthesized in the Golgi and ER, rather than 
true cancer neoantigens. To validate that the peptide antigens we had tested were O-
GlcNAcylated, an in vitro enzyme reaction was used. β1-4-galactosyltransferase (GalT1) 
was shown to transfer N-azidoacetylgalactosamine (GalNAz) to four peptides (IPVsSHNSL 
and (me-)RPPItQSSL) in the ALL sample. Additionally, we found that synthetic O-
GlcNAcylated vs. O-GalNAcylated peptides could be differentiated based on the relative ion 
abundances observed for fragments derived from the oxonium ion at m/z 204 in the 
corresponding fingerprint region of the HCD mass spectra (Fig.  1D)(29). All of the peptides 
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observed (Table 1) produced HCD spectra with the necessary fingerprint region to confirm 
their identity as O-GlcNAc peptides.  
Ten of the peptides detected were also found with disaccharide units attached to the same 
residues that were O-GlcNAcylated. It was determined that these correspond to a hexose 
bound to a HexNAc, because the oxonium ion observed for all of these peptides occurred at 
m/z 366 (204 +162). This was likely the result of the transfer of galactose to the O-
GlcNAcylated peptide by a β-N-acetylglucosamine β1-4 galactosyltransferase; however, the 
remote possibility that this instead could involve the O-glycan synthetic pathway, in which 
the first residue to be added is a GalNAc and the second is either galactose or GlcNAc, 
needed to be excluded. Again, using synthetic peptides (IPVsSHNSL modified with Gal-
GalNAc and Gal-GlcNAc) the fingerprint patterns for fragmentation of the oxonium ion at m/z 
204 in HCD mass spectra could be distinguished, confirming that none of the disaccharide- 
modified peptides in Table 1 were derived from the O-glycan synthetic pathway.  
Two of the glycosylated peptides in Table 1, APRGnVTSL and KPTLLYnVSL, have 
disaccharide units, Hexose-HexNAc, attached to Asn residues. Both peptides have 
consensus sequences, NX(S/T), for attachment of N-linked oligosaccharides. We conclude, 
therefore, that the observed Hexose-GlcNAc disaccharide units attached to Asn in these 
peptides probably result from degradation of the N-linked oligosaccharide structures to a 
single N-linked GlcNAc that then accepts a hexose such as galactose (from a β-N-
acetylglucosamine β1-4 galactosyl- transferase).  This is a novel finding, as the enzyme N-
glycanase1 is responsible for removing all N-linked glycosylation prior to loading onto MHC 
class I molecules, potentially suggesting a new source of neoantigens in leukemia(31). 
Leukemic glycopeptides elicited potent memory T-cell responses in healthy donors 
Previous studies have highlighted how post-translationally modified antigens can be 
immunogenic, with immunity against leukemia-associated MHC class I phosphopeptides 
having been shown to be present in healthy individuals. Immunity against naturally 
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processed MHC class-I O-GlcNAc or methylated peptides has not been studied, but we 
hypothesized that it may exist in healthy individuals. Immunogenicity in healthy donors was 
assessed using seven of the O-GlcNAcylated peptides discovered on leukemic cells (Fig.  
2A-E and Supplementary Figs. S2-S5). Five of the seven (71%) HLA-B*0702 
glycopeptides were immunogenic—heterogeneous responses were seen, with both intra- 
and inter-donor variation (Fig.  2B and C). The responses were further validated using IFNγ 
ELISpot (Supplementary Fig. S5). All healthy donors had immunity to at least one of the 
glycopeptides and two had strong responses, similar to the magnitude of responses against 
chronic viral antigens. Degranulation was assessed as a proxy for killing (Fig.  2C) and 
despite some background staining, degranulation significantly correlated with multifunctional 
cytokine responses (Fig.  2D), suggesting that these T cells targeting O-GlcNAcylated 
peptide antigens have a cytotoxic phenotype. Furthermore, these T cells appeared to be 
largely the memory phenotypes (Fig.  2E).    
Modifications of a methylated glycopeptide specifically targeted by cytotoxic T cells 
As responses were seen against the intriguing methylated glycopeptide ((me-R)PPI(GlcNAc-
T)QSSL) in 4/5 (80%) of healthy donors tested, two being potent, these responses were 
further analyzed using peptides that were either methylated or glycosylated. Whereas no T-
cell responses were seen against the unmodified peptide, responses in different individuals 
were seen targeting either the glycosylated or the methylated peptide (Fig.  3A and S6). In 
the two donors with potent responses to the methylated glycopeptides, \fewer T cells 
recognized the glycopeptide alone, suggesting that the methylation may somehow increase 
immunogenicity. To assess this further, a T-cell line was initiated using the methylated 
glycopeptide. After culture, around 18% of T cells were shown to be specific for the 
methylated glycopeptide (Fig.  3B and Supplementary Fig. S6). Autologous transformed B 
cells were pulsed with modified and unmodified peptides and killing by the T-cell line 
assessed. Specific killing was seen of the B cells pulsed with methylated, O-GlcNAcylated 
and doubly modified peptide, but not with the unmodified peptide (Fig.  3C). These results 
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suggest that we may have identified modified peptides targeted by the endogenous anti-
leukemia T-cell response, which may lead to fruitful targets for novel immunotherapeutics. 
Discussion 
We outline here three methodologies for the identification of MHC class I peptides containing 
a little-known PTM, O-GlcNAc, a potential class of cancer neoantigens. Utilizing these 
methods, we identified 36 GlcNAcylated peptides from primary leukemia samples, and 
showed that a memory T-cell response against a subset of these antigens could be found in 
healthy donors. We also have identified peptides that contained other moieties—not 
previously seen on MHC class I peptides from cancer samples—namely methyl, 
disaccharide, and N-linked GlcNAc groups. Peptides containing these PTMs offer a hitherto 
untapped source of neoantigens in leukemia. 
These neoantigens created by PTMs may be found on leukemic cells because of their 
aberrant cell signaling. This has been reported for phosphopeptide leukemia antigens and 
O-GlcNAcylation sites are usually identical, or in close proximity, to those that get 
phosphorylated(17, 20). Aberrant O-GlcNAcylation has been shown to correlate with 
augmented cancer cell proliferation, survival, invasion, and metastasis (21). The essential 
nature of these pathways to the leukemic cells suggests that these PTM neoantigens may 
not be patient-specific, as seen with the mutated neoantigens, but common across patients 
of the same HLA-type (7, 8). Indeed, we identified many of them on multiple samples from 
leukemia patients, even those with different clinical types. Around a quarter (7/32) of the 
proteins that the PTM peptides derived from are associated with key cancer pathways (as 
defined by the NCI pathway interaction database). Antigens from these key signaling 
pathways are ideal targets for immunotherapies since the leukemic cell is unlikely to be able 
to survive without these pathways, reducing the risk of immune escape. Although further 
work is required to ensure that these PTM peptides are truly cancer neoantigens and not 
found in healthy tissues, they may provide an attractive new avenue for immunotherapeutic 
targeting. 
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Not only are these neoantigens present on leukemia samples, but positional analysis 
indicates that the GlcNAc residues may be optimally positioned for T-cell recognition. The 
GlcNAc group is in the middle of the peptide (up to 34/36; 62% P4, 18% P5, 21% equivocal 
P4/P5; Supplementary Fig. S7), identical to the preferred position of phosphate groups in 
phosphopeptides, and where structural studies have revealed that the CDR3 regions of the 
TCR loops around the center of the peptide(32). Indeed, previous structural studies in mouse 
of TCR binding have demonstrated that GlcNAc modified antigens are recognized in this 
manner (22). 
We saw potent multifunctional memory T-cell responses against these O-GlcNAcylated 
leukemia antigens in healthy donors, suggesting that these neoantigens may reflect an 
endogenous immunosurveillance system against leukemia). Not only did healthy donor T 
cells recognize the PTM neoantigen, but we also showed that they could specifically kill cells 
presenting modified peptides. Therefore, we would not expect targeting of these antigens to 
be compromised by self-tolerance, as may be seen with overexpressed antigens. What is 
more, if healthy donors have cytotoxic memory T cells targeting these PTM neoantigens 
without autoimmunity, targeted therapies against these neoantigens may have low toxicity. 
The most immunogenic peptide identified was me-RPPItQSSL, containing both a methylated 
arginine and O-GlcNAcylated serine.  It is tempting to speculate that combined modifications 
lead to the most dramatic structural change and, therefore, peptides more antigenically 
distinct from self. We showed that T cells may recognize and kill cells presenting this peptide 
with either the methylation, or the O-GlcNAc modification, but not the unmodified peptide. 
This potent antigen, targetable by T cells from several healthy donors, is an attractive target 
for the development of immunotherapeutics. We are expanding this work to identify O-
GlcNAcylated antigens from patients with other HLA-types and cancers and in the process of 
developing methods that allow for the identification of methylated peptide antigens from 
MHC class I. 
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Overall, this work identified both glycosylated and methylated residues as potent classes of 
tumor antigens, broadening the availability of immunotherapy targets, and potentially yielding 
safe and effective therapeutics for leukemia. 
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Table 1.  O-GlcNAcylated peptides presented by HLA B*0702 Class I MHC molecules on leukemia
# Sequence Start - Stop UniProt Tumor Source Protein 
1a APP(sts)AAAL 405-414 Q86TM6 ALL, CLL1 E3 Ubiquitin-protein ligase synoviolin
2b APRGnVTSL  60-68 Q9NR96 CLL1, CLL2 Toll-like receptor 9 
3 APRtNGVAM 187-195 Q92567 ALL, CLL1, CLL2 Protein FAM168A 
4 APTsAAAL 1116-1123 Q86Z02 ALL Homeodomain-interacting protein kinase 1
5 APVsASASV 1807-1815 Q9Y520 ALL Protein PRRC2C 
6 APVsSKSSL 850-858 Q86Z02 ALL, CLL1, CLL2 Homeodomain-interacting protein kinase 1
7 EP(sst)VVSL 1076-1085 O75129 ALL Astrotactin-2
8 HPMsTASQV 345-353 Q13492 ALL Clathrin assembly lymphoid myeloid leukemia 
9c HP(sss)AAVL 740-748 Q86XN7 ALL Proline and serine-rich protein 1 
10 HP(sst)ASTAL 3041-3050 Q96T58 ALL Msx2-interacting protein 
11 IPIsLHTSL 1959-1967 Q5JSZ5 ALL Protein PRRC2B 
12 IPTsSVLSL 710-718 O15027 ALL Protein transport protein Sec16A 
13d IPVsKPLSL 104-112 Q16621 AML, ALL, CLL1 Leucine zipper protein 1 
14e IPVsSHNSL 147-155 Q06413 AML, ALL, CLL1,  JY, S, To Myocyte-specific enhancer factor 2C
15f KPP(ts)QSSVL 411-420 Q5T6F2 ALL Ubiquitin associated protein 2 
16g KPPVsFFSL  95-103 Q6PKC3 ALL Thioredoxin domain containing protein 11
17h KPTLLYnVSL  373-381 P04220 CLL1, CLL2 Ig Mu heavy chain disease protein
18 LPRN(st)MM 335-342 Q9NPI6 ALL mRNA-decapping enzyme 1A 
19 LPTsLPSSL 2464-2472 P46531 ALL Neurogenic locus notch homolog protein 1
20i MPVRPTtNTF 218-227 Q7Z3K3  ALL pogo transposable element with ZNF domain
21 NPVsLPSL 831-838 Q6VMQ6 ALL Activating transcription factor 7-interacting protein 
22j PPS(ts)AAAL 405-414 Q86TM6 ALL E3 Ubiquitin-protein ligase synoviolin
23k RPPItQSSL 382-390 Q9P2N5 ALL, S RNA binding protein 27 
24l RPPQsSSVSL   937-946 O15027 ALL Protein transport protein Sec16A 
25 RPP(sss)QQL 1758-1766 Q8WYB5 ALL Histone acetyltransferase KAT6B 
26 RPPVtKASSF 341-350 Q9Y2K5 ALL, CLL1 R3H domain containing protein 2 
27 RPVtASITTM 927-936 Q9ULH7 ALL, CLL1, CLL2, S MKL/myocardin-like protein 2 
28 TPASsRAQTL 2320-2329 Q01082 CLL1 Spectrin beta chain, non-erythrocytic 1
29 TPAsSSSAL 875-883 Q9NPG3 ALL, CLL1 Ubinucleain 1
30 TPIsQAQKL 3024-3032 Q96L91 ALL E1A-binding protein p400 
31 VPAsSTSTL 576-584 Q9NYV4 ALL, CLL1 Cyclin dependent kinase 12 
32 VPTtSSSL 1284-1291 Q14004 ALL Cyclin dependent kinase 13 
33 VPVsGTQGL 93-101 P23511 ALL Nuclear transcription factor Y subunit alpha
34 VPVsNQSSL 146-154 Q14814 ALL Myocyte-specific enhancer factor 2D
35 VPVsSASEL 596-603 Q7Z2W4 ALL Zinc finger CCCH-type, antiviral 1 
36 VPVsVGPSL 1157-1164 Q86Z02 ALL Homeodomain-interacting protein kinase 1
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Figure legends 
 
Table 1.  O-GlcNAcylated peptides presented by HLA B*0702 Class I MHC molecules 
on leukemia 
Thirty-six peptides, often with multiple forms of glycosylation, were isolated from class I MHC 
molecules on several leukemias, cell lines, and healthy tissue.  These sources are indicated 
as follows: CLL1,2; chronic lymphocytic leukemia samples 1 and 2, AML; acute myeloid 
leukemia, ALL; acute lymphoblastic leukemia, J; JY cell line, S; spleen and To; tonsil - see 
Supplementary Table S1.  Small letters, s, t, and n specify Ser, Thr and Asn residues that 
are modified by O-GlcNAc unless otherwise indicated in a footnote.  Parentheses enclose s 
and t residues that could be a site of GlcNAcylation. Samples were independently analyzed 
by MS at least 3 times. 
Footnotes are as follows: 
a) Peptide was detected in a total of five forms: single GlcNac, double GlcNAc, single 
hexose-GlcNAc, single GlcNAc (S6) + hexose- GlcNac (T5), and double hexose-
GlcNAc 
b) N5 is modified by N-linked hexose-GlcNAc 
c) Peptide was detected in two forms, GlcNAc on S4 and two GlcNAcs on S4 and S5. 
d) Peptide was detected in two forms: GlcNAc (S4) and hexose-GlcNAc (S4) 
e) Peptide was detected in four forms: GlcNAc (S4), double GlcNAc (S4, S5), single 
hexose-GlcNAc (S4), and an acetyl-GlcNAc (S4) 
f) Peptide was detected in two forms: GlcNAc and hexose-GlcNAc (T4) 
g) S5 is modified by O-linked hexose-GlcNAc 
h) N7 is modified by N-linked hexose-GlcNAc 
i) Peptide was detected in two forms: hexose-GlcNAc and asymmetric di-methyl (R4) + 
hexose-GlcNAc (T7) 
j) T4 or S5 is modified by O-linked hexose-GlcNAc 
k) Peptide was detected in four forms: GlcNAc (T5), mono-methyl (R1) + GlcNAc (T5), 
asymmetric di-methyl (R1) + GlcNAc (T5), and ), asymmetric di-methyl (R1) + acetyl-
GlcNAc (T5) 
l) S5 is modified by O-linked hexose-GlcNAc 
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Figure 1. The discovery of MHC class I–associated glycopeptides on primary leukemia 
cells 
(A) HCD mass spectrum of the first O-GlcNAcylated peptide detected in ALL, IPVsSHNSL. 
Fragment ions that define the complete amino acid sequence are labelled as b and y. Those 
that have lost the O-GlcNAc moiety are labelled with an asterisk. (B) Fingerprint ions in the 
HCD spectra of O-GlcNAcylated and O-GalNAcylated peptides. Relative abundances of 
fragment ions derived from secondary fragmentation of the oxonium ion at m/z 204 are 
substantially different for O-GlcNAcylated and O-GalNAcylated peptides. (C) Distribution of 
36 HLA-B*07:02–restricted glycopeptides among the different leukemia and healthy cells 
analysed. ALL = acute lymphoblastic leukemia. Healthy cells = healthy donor tonsil/spleen 
cells. LCL = lymphoblastoid cell line. AML = acute myeloid leukemia. CLL = chronic 
lymphocytic leukemia. (D) Number of copies per cell of the O-GlcNAcylated peptides 
identified on ALL versus healthy B cells (purified from a healthy spleen).  
Figure 2. Healthy donor immunity to leukemia-associated posttranslationally-modified 
neoantigens  
(A) Flow cytometry plots showing the gating strategy used in the ICS protocol to determine 
healthy donor immunity to the O-GlcNAcylated peptides (Fig. S4 contains additional plots). 
Immunity to viral antigens was used as an internal control, for comparison. Collated results 
of cytokine production (B) and degranulation (C) by healthy donor T cells in response to 
stimulation with posttranslationally-modified leukemia neoantigens. (D) The correlation 
between the percentage of cells producing cytokine and degranulating for HD1. (E) HD1 T 
cells that produced cytokine in response to stimulation with peptides were also stained with 
surface antibodies for phenotyping (CD27 and CD45RA; Supplementary Fig. S5). CM - 
central memory, N - naïve, EM - effector memory and TEMRA - terminal effector memory. 
Responses were independently verified at least twice. 
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Figure  3. Investigating T-cell recognition of the methylated O-GlcNAc peptide  
(A) Healthy donor immunity to the unmodified, O-GlcNAcylated, methylated and both O-
GlcNAcylated and methylated peptide, measured by cytokine production and degranulation. 
(B) A T-cell line was grown from HD5 against the methylated RPPItQSSL peptide. The 
percentage of cells recognizing the peptide were assessed by overnight stimulation with the 
peptide and detection of CD137 and CD107a surface markers. (C) This T-cell line was using 
a europium release killing assay to assess killing of autologous transformed B cells pulsed 
with different modifications of the peptide. Responses were independently verified at least 
twice. 
 
 



